Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off

Core Insights - Brown Capital Management sold 376,359 shares of Glaukos Corporation for an estimated $34.6 million in Q3, reducing its holding to 762,760 shares valued at $62.2 million [2][3] - The sale decreased Glaukos Corporation's weight in Brown Capital Management's portfolio to 2.6% of 13F assets [3][6] - Glaukos shares have declined approximately 34% over the past year, significantly underperforming the S&P 500, which is up nearly 15% [3] Company Overview - Glaukos Corporation specializes in ophthalmic medical technology, focusing on innovative micro-scale devices and pharmaceutical solutions for glaucoma and related eye disorders [5] - The company reported a total revenue of $433 million and a net income loss of $92.8 million for the trailing twelve months (TTM) [4] - As of the latest market close, Glaukos's stock price was $84.35, with a market capitalization of $4.8 billion [4] Recent Performance - The company's revenue grew by 28% year-over-year to $105.5 million, but it faced larger-than-expected losses and rising expenses, leading to a decline in stock price [7] - Management anticipates sales between $475 million and $485 million for 2025, while acknowledging challenges related to currency exchange and market entry [8] Strategic Positioning - Glaukos aims to expand its product portfolio and leverage proprietary technology platforms to meet unmet clinical needs in ophthalmology [5] - The company's competitive advantage lies in its focus on minimally invasive therapies and a robust pipeline targeting multiple ophthalmic indications [5][8]